Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study
C. Vigneron (Paris, France), A. Vivot (Paris, France), M. Jamme (Poissy, France), A. Gibelin (Paris, France), G. Briend (Paris, France), J. Pastré (Paris, France), B. Planquette (Paris, France), G. Meyer (Paris, France), O. Sanchez (Paris, France)
Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Vigneron (Paris, France), A. Vivot (Paris, France), M. Jamme (Poissy, France), A. Gibelin (Paris, France), G. Briend (Paris, France), J. Pastré (Paris, France), B. Planquette (Paris, France), G. Meyer (Paris, France), O. Sanchez (Paris, France). Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study. 3654
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: